DBV Technologies (DBVT) Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DBVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €12.90 |
| 52 Week High | €14.44 |
| 52 Week Low | €2.20 |
| Beta | 0.43 |
| 1 Month Change | 43.88% |
| 3 Month Change | 17.17% |
| 1 Year Change | 268.57% |
| 3 Year Change | -22.29% |
| 5 Year Change | -27.93% |
| Change since IPO | -95.47% |
Recent News & Updates
Shareholder Returns
| DBVT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 40.8% | 4.5% | 0.9% |
| 1Y | 268.6% | 0.5% | 18.4% |
Return vs Industry: DBVT exceeded the US Biotechs industry which returned -0.3% over the past year.
Return vs Market: DBVT exceeded the US Market which returned 17.7% over the past year.
Price Volatility
| DBVT volatility | |
|---|---|
| DBVT Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DBVT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DBVT's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 109 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBVT fundamental statistics | |
|---|---|
| Market cap | US$385.34m |
| Earnings (TTM) | -US$122.41m |
| Revenue (TTM) | US$3.80m |
Is DBVT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBVT income statement (TTM) | |
|---|---|
| Revenue | US$3.80m |
| Cost of Revenue | US$0 |
| Gross Profit | US$3.80m |
| Other Expenses | US$126.21m |
| Earnings | -US$122.41m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,221.34% |
| Debt/Equity Ratio | 0% |
How did DBVT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 07:01 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DBV Technologies S.A. is covered by 18 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Jonathan Wolleben | Citizens JMP Securities, LLC |